Predictive role of glutathione-s-transferase gene polymorphisms in risk and prognosis of hepatocellular carcinoma

Asian Pacific Journal of Cancer Prevention

Volumn 13, Issue 7, 2012, Pages 3247-3252

  Li, Cheng Gang ^a   Zhao, Zhi Ming ^a   Hu, Ming Geng ^a   Liu, Rong ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

Glutathione S transferases; HCC; Polymorphisms; Risk; Survival

Indexed keywords

EID: 84873583117     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2012.13.7.3247     Document Type: Article

References (40)

1. Abd El-Moneim E, Younis FA, Allam N, Gameel K, Osman M. (2008). Gene deletion of glutathione S-transferase M1 and T1 and risk factors of hepatocellular carcinoma in Egyptian patients. Egypt J Immunol, 15, 125-34.
2. Ambrosone CB, Sweeney C, Coles BF, et al. (2001). Polymorphisms in glutathione S-transferases (GSTM1 and GSTT1) and survival after treatment for breast cancer. Cancer Res, 61, 7130-5.
3. Asim M, Khan LA, Husain SA, et al. (2010). Genetic polymorphism of glutathione S transferases M1 and T1 in Indian patients with hepatocellular carcinoma. Dis Markers, 28, 369-76.
4. Borst L, Buchard A, Rosthøj S, et al. (2012). Gene dose effects of GSTM1, GSTT1 and GSTP1 polymorphisms on outcome in childhood acute lymphoblastic leukemia. J Pediatr Hematol Oncol, 34, 38-42.
5. Boyer TD, Kenney WC. (1985). Preparation, characterization and properties of glutathione S-transferases. In: Zakim D, Vessey D, eds. Biochemical pharmacology and toxicology. New York, NY: John Wiley & Sons.
6. Chen B, Cao L, Zhou Y, et al. (2010). Glutathione S-transferase T1 (GSTT1) gene polymorphism and gastric cancer susceptibility: a meta-analysis of epidemiologic studies. Dig Dis Sci, 55, 1831-8.
7. Chen YL, Tseng HS, Kuo WH, et al. (2010). Glutathione S-Transferase P1 (GSTP1) gene polymorphism increases age-related susceptibility to hepatocellular carcinoma. BMC Med Genet, 11, 46.
8. Dalhoff K, Buus Jensen K, Enghusen Poulsen H. (2005). Cancer and molecular biomarkers of phase 2. Methods Enzymol, 400, 618-27.
9. Giera S, Braeuning A, Köhle C, Bursch W, Metzger U, Buchmann A, Schwarz M. (2010).Wnt/beta-catenin signaling activates and determines hepatic zonal expression of glutathione S-transferases in mouse liver. Toxicol Sci, 115, 22-33.
10. Goekkurt E, Hoehn S, Wolschke C, et al. (2006). Polymorphisms of glutathione S-transferases (GST) and thymidylate synthase (TS)-novel predictors for response and survival in gastric cancer patients. Br J Cancer, 94, 281-6.
11. Han X, Xing Q, Li Y, Sun J, Ji H, Huazheng P, Jun L. (2012). Study on the DNA Repair Gene XRCC1 and XRCC3 Polymorphism in Prediction and Prognosis of Hepatocellular Carcinoma Risk.Hepatogastroenterology, 59(119). doi:10.5754/hge12096.
12. Hayes JD, Pulford DJ. (1995). The glutathione S-transferase supergene family: regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance. Crit Rev Biochem Mol Biol, 30, 445-600.
13. Hayes JD, Strange RC. (2000). Glutathione S-transferase polymorphisms and their biological consequences. Pharmacology, 61, 154-66.
14. Hohaus S, Di Ruscio A, Di Febo A, et al. (2005). Glutathione S-transferase P1 genotype and prognosis in Hodgkin's lymphoma. Clin Cancer Res, 11, 2175-9.
15. Kao CC, Chen MK, Kuo WH, et al. (2010). Influence of glutathione-S-transferase theta (GSTT1) and micro (GSTM1) gene polymorphisms on the susceptibility of hepatocellular carcinoma in Taiwan. J Surg Oncol, 102, 301-7.
16. Kiran M, Chawla YK, Kaur J. (2008). Glutathione-S-transferase and microsomal epoxide hydrolase polymorphism and viral-related hepatocellular carcinoma risk in India. DNA Cell Biol, 27, 687-94.
17. IARC. Globocan 2008: Liver Cancer Incidence and Mortality Worldwide in 2008 Summary. AIRC, 2008. http://globocan.iarc.fr/factsheets/cancers/liver.asp.
18. Mahimkar MB, Samant TA, Kannan S, et al. (2011). Polymorphisms in GSTM1 and XPD genes predict clinical outcome in advanced oral cancer patients treated with postoperative radiotherapy. Mol Carcinog, Dec 28.
19. Moy KA, Yuan JM, Chung FL, et al. (2009). YuIsothiocyanates, glutathione S-transferase M1 and T1 polymorphisms and gastric cancer risk: a prospective study of men in Shanghai, China. Int J Cancer, 125, 2652-9.
20. Nguyen TV, Janssen MJ, van Oijen MG, et al. (2010). Genetic polymorphisms in GSTA1, GSTP1, GSTT1, and GSTM1 and gastric cancer risk in a Vietnamese population. Oncol Res, 18, 349-55.
21. Ott K, Lordick F, Becker K, et al. (2008). Glutathione-Stransferase P1, T1 and M1 genetic polymorphisms in neoadjuvant-treated locally advanced gastric cancer: GSTM1-present genotype is associated with better prognosis in completely resected patients. Int J Colorectal Dis, 23, 773-82.
22. Parkin DM. (2001). Global cancer statistics in the year 2000. Lancet Oncol, 2, 533-43.
23. Pemble S, Schroeder KR, Spencer SR, et al. (1994). Human glutathione S-transferase theta (GSTT1): cDNA cloning and the characterization of a genetic polymorphism. Biochem J, 300, 271-6.
24. Piao JM, Shin MH, Kweon SS, et al. (2009). Glutathione-Stransferase. (GSTM1, GSTT1) and the risk of gastrointestinal cancer in a Korean population. World J Gastroenterol, 15, 5716-21.
25. Reszka E, Wasowicz W, Gromadzinska J. (2006). Genetic polymorphism of xenobiotic metabolising enzymes, diet and cancer susceptibility. Br J Nutr, 96, 609-19.
26. Roth MJ, Abnet CC, Johnson LL, et al. (2004). Polymorphic variation of Cyp1A1 is associated with the risk of gastric cardia cancer: a prospective case cohort study of cytochrome P-450 1A1 and GST enzymes. Cancer Causes Control, 15, 1077-83.
27. Saip R, Sen F, Vural B, et al. (2011). Glutathione S-transferase P1 polymorphisms are associated with time to tumor progression in small cell lung cancer patients. J BUON, 16, 241-6.
28. Shiga H, Heath EI, Rasmussen AA, et al. (1995). Prognostic value of p53, glutathione S-transferase pi, and thymidylate synthase for neoadjuvant cisplatin-based chemotherapy in head and neck cancer. Clin Cancer Res, 5, 4097-104.
29. Srivastava SK, Singhal SS, Hu X, et al. (1999). Differential catalytic efficiency of allelic variants of human glutathione S-transferase Pi in catalyzing the glutathione conjugation of thiotepa. Arch Biochem Biophys, 366, 89-94.
30. Stoehlmacher J, Park DJ, Zhang W, et al. (2002). Association between glutathione S-transferase P1, T1, and M1 genetic polymorphism and survival of patients with metastatic colorectal cancer. J Natl Cancer Inst, 19, 936-42.
31. Suneetha KJ, Nancy KN, Rajalekshmy KR, et al. (2011). Role of glutathione-s-transferase and CYP1A1*2A polymorphisms in the therapy outcome of south Indian acute lymphoblastic leukemia patients. Indian J Med Paediatr Oncol, 32, 25-9.
32. Sweeney C, McClure GY, Fares MY, et al. (2000). Association between survival after treatment for breast cancer and glutathione S-transferase P1 Ile105Val polymorphism. Cancer Res, 60, 5621-4.
33. Tahara T, Shibata T, Nakamura M, et al. (2011). Effect of genetic polymorphisms related to DNA repair and the xenobiotic pathway on the prognosis and survival of gastric cancer patients. Anticancer Res., 31, 705-10.
34. Watson MA, Stewart RK, Smith GB, et al. (1998). Human glutathione Stransferase P1 polymorphisms: relationship to lung tissue enzyme activity and population frequency distribution. Carcinogenesis, 19, 275-80.
35. White DL, Li D, Nurgalieva Z, El-Serag HB. (2008). Genetic variants of glutathione S-transferase as possible risk factors for hepatocellular carcinoma: a HuGE systematic review and meta-analysis. Am J Epidemiol, 167, 377-89.
36. Wideroff L, Vaughan TL, Farin FM, et al. (2007). GST, NAT1, CYP1A1 polymorphisms and risk of esophageal and gastric adenocarcinomas. Cancer Detect Prev, 31, 233-6.
37. Wiencke JK, Kelsey KT, Lamela RA, et al. (1990). Human glutathione Stransferase deficiency as a marker of susceptibility to epoxide-induced cytogenetic damage. Cancer Res, 50, 1585-90.
38. Yang G, Shu XO, Ruan ZX, et al. (2005). Genetic polymorphisms in glutathione-S-transferase genes (GSTM1, GSTT1, GSTP1) and survival after chemotherapy for invasive breast carcinoma. Cancer, 103, 52-8.
39. Zha Y, Cun Y, Zhang Q, Li Y, Tan J. (2012). Prognostic value of expression of Kit67, p53, TopoIIα and GSTP1 for curatively resected advanced gastric cancer patients receiving adjuvant paclitaxel plus capecitabine chemotherapy. Hepatogastroenterology, 59, 1327-32.
40. Zhang YJ, Chen Y, Ahsan H, Lunn RM, Chen SY, Lee PH, Chen CJ, Santella RM. (2005) Silencing of glutathione S-transferase P1 by promoter hypermethylation and its relationship to environmental chemical carcinogens in hepatocellular carcinoma. Cancer Lett, 221, 135-43.